Effects of HIIT vs Strength Training on Health in Postmenopausal Women with Breast Cancer
Postmenopausal Oncological Women Exercising for Recover Their Health. Associations and Changes in Metabolic Flexibility and Autonomic Control After Two Training Programs (Muscle Power vs Metabolic Power): the POWER Health Study
This study is testing whether high-intensity interval training or strength training can improve heart health and overall well-being in postmenopausal women who have had breast cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 56 (estimated) |
| Ages | 35 Years to 75 Years |
| Sex | Female |
| Sponsor | University of Valencia Academic / other |
| Locations | 1 site (Valencia, Valencia) |
| Trial ID | NCT06336070 on ClinicalTrials.gov |
What this trial studies
The POWER Health study is a randomized clinical trial designed to evaluate metabolic flexibility and autonomic function in postmenopausal women with a history of breast cancer compared to untreated controls. Participants will undergo two different 8-week supervised exercise interventions: high-intensity interval training (HIIT) aimed at improving metabolic power and strength training focused on enhancing muscle power. The study aims to determine the impact of these interventions on cardiovascular health and overall well-being in this population. By comparing these two approaches, the trial seeks to identify the most effective exercise regimen for improving health outcomes in postmenopausal oncological women.
Who should consider this trial
Good fit: Ideal candidates include postmenopausal women aged 35 to 75 who are either relapse-free from breast cancer or have not been diagnosed with cancer in the last 15 years.
Not a fit: Patients with medical contraindications to exercise or those who have planned surgeries during the intervention period may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved cardiovascular health and quality of life for postmenopausal women with a history of breast cancer.
How similar studies have performed: Previous studies have shown positive outcomes with exercise interventions in cancer survivors, suggesting that this approach may be beneficial, although the specific comparison of HIIT and strength training in this context is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed of relapse free-cancer (RFC) or patients not diagnosed of any cancer at least the last 15 years (CG) * Aged between 35 and 75 years * Diagnostic of breast cancer (i.e., including ductal carcinoma, invasive carcinoma, triple negative; RFC) or physiological menopause (CG) * Not participating in a nutritional/dietary intervention * Not being physically active (i.e., not to be participating in any physical exercise program in the last 3 months, or performing less than 600 metabolic equivalents (METS)/week of moderate-vigorous physical activity). * To be capable and willing to provide informed consent * Not to suffer from any specific condition that may impede testing of the study hypothesis or make it unsafe to engage in the exercise intervention (i.e., determined by the research staff). Exclusion Criteria: * Medical contraindication for being engaged in an exercise. * Additional surgery planned within the intervention * Consuming usually betablocker or any drugs alterning nervous system functioning * History of another primary invasive cancer (RFC) or suffer a serious chronic illness (CG) * To present any of the following cardiac conditions: (i) myocardial infarction or coronary revascularization procedure within prior 3 months, (ii) uncontrolled hypertension (i.e., systolic ≥180 mmHg or diastolic ≥100 mmHg), (iii) uncontrolled arrhythmias (iv) valvular disease clinically significant, (v) decompensated heart failure or (vi) to suffer from known aortic aneurysm.
Where this trial is running
Valencia, Valencia
- Faculty of Physical Activity and Sport Sciences — Valencia, Valencia, Spain (Recruiting)
Study contacts
- Principal investigator: Cristina Blasco Lafarga, Tenured Professor — University of Valencia
- Study coordinator: Cristina Blasco Lafarga, Tenured Professor
- Email: m.cristina.blasco@uv.es
- Phone: 64372
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.